Beximco Pharmaceuticals Limited
BXP.L · LSE
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | £5,866,771 | £4,524,468 | £5,123,137 | £5,127,694 |
| Dep. & Amort. | £1,993,810 | £2,060,503 | £370,238 | £1,114,187 |
| Deferred Tax | £0 | £0 | £0 | £0 |
| Stock-Based Comp. | £0 | £0 | £0 | £0 |
| Change in WC | £433,351 | -£734,170 | -£1,909,440 | -£652,682 |
| Other Non-Cash | £70,534 | £233,985 | £1,630,241 | £434,065 |
| Operating Cash Flow | £8,364,466 | £6,084,787 | £5,493,375 | £6,023,264 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -£1,993,730 | -£2,410,765 | -£2,939,498 | -£2,558,418 |
| Net Acquisitions | £0 | £0 | -£4,766,636 | £0 |
| Inv. Purchases | £0 | £0 | £0 | £0 |
| Inv. Sales/Matur. | £0 | £0 | £0 | £0 |
| Other Inv. Act. | -£412,729 | -£206,252 | £26,079 | £33,772 |
| Investing Cash Flow | -£2,406,459 | -£2,617,018 | -£7,680,054 | -£2,524,646 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -£4,673,973 | -£1,992,647 | £4,238,324 | -£504,637 |
| Stock Issued | £0 | £0 | £0 | £0 |
| Stock Repurch. | £0 | £0 | £0 | £0 |
| Dividends Paid | -£1,585,901 | -£1,567,923 | -£1,623,099 | -£578,351 |
| Other Fin. Act. | £0 | £0 | £0 | -£2,375,180 |
| Financing Cash Flow | -£6,259,874 | -£3,560,571 | £2,615,225 | -£3,458,168 |
| Forex Effect | £20,285 | £59,814 | £45,363 | £0 |
| Net Chg. in Cash | -£281,581 | -£32,988 | £194,710 | £40,450 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | £1,135,686 | £1,168,674 | £973,964 | £635,017 |
| End Cash | £854,106 | £1,135,686 | £1,168,674 | £675,467 |
| Free Cash Flow | £6,129,909 | £3,374,759 | £2,553,877 | £3,464,846 |